Saturday 17 October 2026
Export PHAR’s income statement to Excel — free account
Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.36
0.27
−2.80%
Follow PHAR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 6 | 6 | 5 | — | — | — | — |
P/E ratio |
441.75 | 0.00 | 0.00 | 60.74 | 63.00 | 77.31 | 80.75 | 80.75 | 80.75 | 80.75 |
Altman Z-Score |
3.88 | 2.59 | 2.15 | 2.34 | 1.95 | 3.12 | — | — | — | — |
P/S ratio |
3.24 | 2.27 | 3.08 | 3.65 | 29.41 | 44.99 | 52.19 | 52.19 | 52.19 | 52.19 |
Altman Z″-Score (non-manufacturers) |
2.28 | 2.26 | 2.37 | 2.65 | 2.33 | 2.66 | (1.44) | — | — | (7.55) |
P/FCF ratio |
22.56 | 0.00 | 0.00 | 50.50 | 314.61 | 79.97 | 57.90 | 57.90 | 57.90 | 57.90 |
Beneish M-Score |
(2.78) | (2.36) | (1.94) | (2.71) | (2.95) | (2.98) | (2.59) | — | — | — |
P/Operating CF |
113.67 | 72.45 | 65.27 | 138.41 | 382.16 | 489.96 | 164.75 | 164.75 | 164.75 | 164.75 |
P/B ratio |
4.39 | 3.06 | 3.45 | 3.69 | 30.09 | 52.65 | 66.90 | 66.90 | 66.90 | 66.90 |
Price to Tangible BV |
8.60 | 4.22 | 5.12 | 5.83 | 53.21 | 108.09 | 153.70 | 153.70 | 153.70 | 153.70 |
EV/Sales |
3.02 | 1.99 | 2.77 | 3.29 | 29.25 | 44.79 | 52.01 | 52.01 | 52.01 | 52.01 |
EV/EBITDA |
30.63 | 79.28 | 64.58 | 41.83 | 188.57 | 114.81 | 127.13 | 127.13 | 127.13 | 127.13 |
EV/Operating CF |
20.75 | (329.00) | (39.33) | 25.07 | 167.87 | 74.71 | 57.70 | 57.70 | 57.70 | 57.70 |
EV/FCF |
21.04 | (184.03) | (34.00) | 45.55 | 312.97 | 79.60 | 57.70 | 57.70 | 57.70 | 57.70 |
Quick Ratio |
2.03 | 3.02 | 3.33 | 3.94 | 4.75 | 3.15 | 0.90 | 1.17 | 1.13 | 0.84 |
Current Ratio |
2.59 | 3.77 | 4.06 | 4.65 | 5.33 | 3.43 | 1.05 | 1.40 | 1.45 | 1.21 |
Net Debt/EBITDA |
(2.21) | (11.48) | (7.12) | (2.36) | (1.55) | (0.64) | (0.25) | (0.18) | 0.96 | (3.29) |
Debt/Assets |
19.61% | 20.60% | 29.91% | 31.33% | 35.46% | 36.27% | 21.90% | 33.99% | 0.00% | 53.16% |
Debt/Equity |
0.35 | 0.37 | 0.63 | 0.65 | 0.73 | 0.83 | 0.48 | 1.18 | 5.10 | 2.45 |
Asset Turnover |
0.84 | 0.69 | 0.55 | 0.50 | 0.49 | 0.63 | 0.75 | 0.82 | 1.62 | 0.10 |
Operating CF/Net income |
19.19 | 0.15 | 1.64 | 1.64 | 2.37 | 2.22 | 1.84 | 1.17 | (0.40) | 0.57 |
Capex/Depreciation |
(0.07) | (0.05) | (0.09) | (0.15) | (0.85) | (1.84) | (4.39) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | — | — | — | — | 0.00 | 0.00 | (3.80) |
| 1.14% | (5.38%) | (4.98%) | 6.88% | 8.50% | 25.11% | 43.08% | 63.57% | (380.21%) | (76.40%) | |
| 0.63% | (2.74%) | (2.37%) | 3.32% | 3.92% | 11.20% | 16.14% | 15.12% | (137.67%) | (11.06%) | |
ROIC |
8.27% | (3.97%) | (2.34%) | 8.73% | 5.98% | 36.93% | 43.09% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
1.49% | (5.58%) | (4.25%) | 5.99% | 7.41% | 19.01% | 274.83% | 60.60% | (213.33%) | (104.04%) |
Average Days of Receivables |
53.08 | 67.33 | 68.68 | 49.03 | 55.03 | 61.76 | 55.58 | 43.22 | 41.47 | 261.82 |
Research and Development Expense of Revenue |
26.68% | 27.98% | 28.09% | 25.55% | 35.38% | 18.15% | 16.78% | 20.71% | 20.26% | 92.81% |
Selling, General and Administrative Expense of Revenue |
56.08% | 63.75% | 73.34% | 64.11% | 48.48% | 35.67% | 34.80% | 32.50% | 38.55% | 47.74% |
Intangible Assets out of Total Assets |
0.27 | 0.15 | 0.15 | 0.18 | 0.21 | 0.22 | 0.31 | 0.24 | 0.00 | 0.45 |
Share Based Compensation of Revenue |
3.66% | 3.78% | 3.77% | 3.11% | 4.55% | 3.08% | 2.26% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.06 | 0.15 | 0.10 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
1.90 | 0.00 | 0.00 | 3.65 | 0.97 | 1.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.23% | (1.79%) | (1.74%) | 1.65% | 1.59% | 1.29% | 1.24% | 1.24% | 1.24% | 1.24% |
Free Cash Flow Yield |
4.43% | (0.47%) | (2.65%) | 1.98% | 0.32% | 1.25% | 1.73% | 1.73% | 1.73% | 1.73% |
Revenue per Share |
5.46 | 4.43 | 3.73 | 3.17 | 3.10 | 3.33 | 3.02 | 2.53 | 0.22 | 0.04 |
Operating CF per Share |
0.79 | (0.03) | (0.26) | 0.35 | 0.59 | 1.31 | 1.19 | 0.55 | 0.07 | (0.03) |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | (0.26) | (0.24) | (0.41) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.78 | (0.04) | (0.29) | 0.32 | 0.33 | 1.07 | 0.78 | 0.55 | 0.07 | (0.03) |
Cash per Share |
2.61 | 2.50 | 3.25 | 3.20 | 2.99 | 3.24 | 1.19 | 1.50 | 0.14 | 0.08 |
Shareholders Equity per Share |
4.02 | 3.29 | 3.33 | 3.15 | 3.00 | 2.88 | 1.87 | 1.16 | 0.04 | 0.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.02 | 3.29 | 3.33 | 3.15 | 3.00 | 2.88 | 1.87 | 1.16 | 0.04 | 0.07 |
Free Cash Flow |
53.95 | (2.59) | (18.77) | 20.48 | 21.13 | 68.33 | 49.04 | 33.69 | 36.55 | (10.53) |
Working Capital |
183.68 | 204.64 | 238.37 | 217.80 | 202.67 | 186.36 | 5.17 | 37.75 | 33.14 | 11.38 |
Capital Expenditures |
(0.75) | (0.80) | (1.46) | (1.98) | (16.72) | (15.30) | (25.44) | (4.33) | (7.28) | (1.59) |
Net Current Asset Value |
76.61 | 99.52 | 72.27 | 56.34 | 45.05 | 28.19 | (19.07) | (42.96) | (74.49) | (39.08) |
EV/EBIT |
43.93 | 0.00 | 0.00 | 8.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | 0.08 | 0.07 | 0.13 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
47.10 | 0.00 | 0.00 | 9.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.55 | 2.07 | 1.64 | 1.27 | 1.48 | 0.68 | 0.61 | 0.47 | 0.41 | 0.13 |
Cash ROIC |
9.72% | (0.55%) | (3.29%) | 3.75% | 4.02% | 12.62% | 19.82% | 13.63% | 19.32% | (7.89%) |
Accounts Receivable Turnover |
6.87 | 5.89 | 6.65 | 7.14 | 6.04 | 6.56 | 8.02 | 10.13 | 8.90 | 1.38 |
Accounts Payable Turnover |
0.53 | 0.51 | 0.40 | 0.36 | 0.47 | 0.53 | 0.99 | 3.14 | 2.20 | 0.66 |
Inventory Turnover |
0.75 | 0.63 | 0.51 | 0.50 | 0.87 | 1.26 | 1.32 | 1.42 | 0.93 | 0.28 |
Average Days of Payables |
849.52 | 686.83 | 1,050.00 | 1,131.97 | 733.26 | 739.12 | 619.53 | 93.51 | 217.97 | 379.29 |
Days of Inventory on Hand |
520.64 | 574.57 | 821.73 | 879.68 | 471.49 | 328.06 | 247.27 | 243.78 | 423.78 | 1,203.98 |
Average Receivables |
54.76 | 50.49 | 36.89 | 28.80 | 32.94 | 32.36 | 23.61 | 15.33 | 12.13 | 12.13 |
Average Payables |
86.26 | 69.57 | 63.50 | 48.47 | 45.07 | 44.13 | 24.12 | 9.50 | 8.66 | 8.66 |
Average Inventory |
60.31 | 56.24 | 49.54 | 34.82 | 24.23 | 18.68 | 18.05 | 21.00 | 20.49 | 20.49 |
Average Assets |
449.97 | 431.42 | 444.33 | 411.56 | 407.88 | 337.02 | 251.11 | 190.04 | 66.73 | 166.84 |
Average Common Equity |
249.08 | 219.92 | 211.71 | 198.78 | 188.18 | 150.34 | 94.11 | 45.19 | 24.16 | 24.16 |
Columns are period end dates